title: [Sound therapy in sudden deafness].
abstract: OBJECTIVE
  Idiopathic sudden sensorineural hearing loss is a hearing disorder of unknown cause. The spontaneous recovery rate ranges from 50 to 75% of the patients. Scientific experiments on animals support the present study in patients with sudden deafness treated with sounds.
  
  
  METHODS
  During the period 2003-2009, patients with idiopathic sudden sensorineural hearing loss were administered steroids, piracetam and antioxidants, together with the addition of sounds by means of music and words.
  
  
  RESULTS
  Comparing the results of patients treated with medication (n=65) and those treated with medication and sounds (n=67), it was observed that patients treated with medication and sounds had higher recovery. Within the group of patients treated with medication and sounds, 25 (37%) experienced complete recovery, 28 (42%) good recovery, 11 (16%) slight recovery and 3 (5%) poor or no recovery.
  
  
  CONCLUSIONS
  The patients who recovered more than half of their audition accounted for 54% in the group treated with medication and for 79% in the group of patients receiving medication and sounds. Auditory recuperation showed no alterations, at least up to 12 months after therapy.
authors.affiliation: UGC Otorrinolaringología, Hospital Universitario Virgen del Rocío, Sevilla, España. malopez@cica.es
authors.forename: Miguel A
authors.initials: MA
authors.lastname: López-González
authors.forename: Esther
authors.initials: E
authors.lastname: Cambil
authors.forename: Antonio
authors.initials: A
authors.lastname: Abrante
authors.forename: Rocío
authors.initials: R
authors.lastname: López-Fernández
authors.forename: Francisco
authors.initials: F
authors.lastname: Esteban
mesh_terms: D000161:Acoustic Stimulation; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D003639:Hearing Loss, Sudden / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D046088:Hearing Loss, Unilateral / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D006320:Hearing Tests; D006801:Humans; D008297:Male; D008875:Middle Aged; D009147:Music Therapy; D009853:Omeprazole / Q000008:administration & dosage / Q000627:therapeutic use*; D010889:Piracetam / Q000008:administration & dosage / Q000627:therapeutic use*; D011282:Pregnenediones / Q000008:administration & dosage / Q000627:therapeutic use*; D020127:Recovery of Function; D012189:Retrospective Studies; D013315:Stress, Psychological / Q000150:complications; D014012:Tinnitus / Q000150:complications; D014717:Vertigo / Q000150:complications; D055815:Young Adult; D024502:alpha-Tocopherol / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; D011282:Pregnenediones; D024502:alpha-Tocopherol; D009853:Omeprazole; C021988:deflazacort; D010889:Piracetam